FRAT2 antibody (AA 131-230) (AbBy Fluor® 350)
-
- Target See all FRAT2 Antibodies
- FRAT2 (Frequently Rearranged in Advanced T-Cell Lymphomas 2 (FRAT2))
-
Binding Specificity
- AA 131-230
-
Reactivity
- Mouse
-
Host
- Rabbit
-
Clonality
- Polyclonal
-
Conjugate
- This FRAT2 antibody is conjugated to AbBy Fluor® 350
-
Application
- Western Blotting (WB), Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p))
- Cross-Reactivity
- Mouse
- Predicted Reactivity
- Human,Rat,Dog,Cow,Sheep
- Purification
- Purified by Protein A.
- Immunogen
- KLH conjugated synthetic peptide derived from human FRAT2
- Isotype
- IgG
- Top Product
- Discover our top product FRAT2 Primary Antibody
-
-
- Application Notes
-
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200 - Restrictions
- For Research Use only
-
- Format
- Liquid
- Concentration
- 1 μg/μL
- Buffer
- Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.
- Preservative
- ProClin
- Precaution of Use
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
- Storage
- -20 °C
- Storage Comment
- Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
- Expiry Date
- 12 months
-
- Target
- FRAT2 (Frequently Rearranged in Advanced T-Cell Lymphomas 2 (FRAT2))
- Alternative Name
- FRAT2 (FRAT2 Products)
- Synonyms
- FRAT2 antibody, FRAT2, WNT signaling pathway regulator antibody, frequently rearranged in advanced T cell lymphomas 2 antibody, frequently rearranged in advanced T-cell lymphomas 2 antibody, FRAT2 antibody, Frat2 antibody
- Background
-
Synonyms: Frequently rearranged in advanced T-cell lymphomas 2 antibodyGSK-3 binding protein FRAT2, FRAT2_HUMAN.
Background: FRAT1 and FRAT2 were originally characterized as proteins frequently rearranged in advanced T cell lymphoma, and they have since been identified as proto-oncogenes involved in tumorigenesis. These proteins share significant homology with the Xenopus glycogen synthase kinase-3 (xGSK-3) binding protein, which is designated GBP and is essential for the formation of the dorsal-ventral axis during embryonic development. Establishment of these embryonic axes is mediated by the Wnt intracellular signaling pathway. Wnt signaling is regulated in part by the activity of GSK-3, which phosphorylates and thereby facilitates the degradation of ?catenin. GBP binds to GSK-3 and inhibits this phosphorylation, resulting in the accumulation of ?catenin and the subsequent transcription of Wnt target genes. Like GBP, FRAT2 has been shown to bind xGSK-3, suggesting that FRAT1 and FRAT2 may be GSK-3 regulatory proteins.
- Gene ID
- 23401
-